Yves A Lussier
- Associate Director, Bio5 Informatics
- Professor, Medicine - (Tenure Track)
- Associate Vice President / Chief Knowledge Officer, UA - Health Sciences Center
- Associate Director, Cancer Informatics / Precision Health - UA Cancer Center
- Professor, Statistics-GIDP
- Professor, Clinical Translational Sciences
Yves A. Lussier, MD, Fellow ACMI. Dr. Lussier is the Associate Vice President for Information Science and Chief Knowledge Officer of the UA Arizona Health Sciences (UAHS), Founding Director of the Center for Biomedical Informatics and Biostatistics, Associate Director for Cancer Informatics and Precision Health for the University of Arizona Cancer Center, and Professor of Medicine.
His research group conducts pioneering hypothesis-driven computational modeling predictions in precision medicine that are then validated in vitro, in vivo and in clinical trials. As a leader of the fields of translational bioinformatics and of Data Science-augmented precision medicine, he has launched successful companies and international conferences, authored 198 publications, and delivered more than 110 invited presentations in precision medicine, systems medicine, and translational bioinformatics, including 26 opening keynotes at international conferences. He has been awarded $190,000,000 in grants as principal, core leader, or co-investigator, and mentored 55 graduate and postgraduate students as well as 42 junior faculty members. Dr. Lussier’s honors include three IBM Faculty Awards, inducted Fellow of the American College of Medical Informatics (ACMI), 1st recipient of the Columbia University Faculty Mentoring Award, “Ambassador for Health Sciences” at the University of Sherbrooke (Canada), and 16 outstanding publication awards from the American Medical Informatics Association (AMIA), the International Society for Computational Biology (ISCB), and the Translational Bioinformatics Conference (TBC). Last year, Dr. Lussier was invited among ten USA academic leaders invited by the White House for its Precision Medicine Summit (2/2016), where the University of Arizona Center for Biomedical Informatics and Biostatistics that he directs has committed $20M of R&D in bringing precision medicine to practice.
His R&D teams have developed many precision medicine solutions powered with ontologies: (i) the 1st tablet-based electronic medical records anchored on the 1st commercial ontology (Purkinje.com, 1991-; 65,000 terms, 7 semantic types; SCAMC 1992), (ii) Vigilens: the 1st ontology-anchored clinical event monitor of the Columbia University New York-Presbyterian Hospital (IBM awards, in operations since 2002). Some of our recent methodological innovations leveraging ontologies and molecular network models led to discoveries confirmed in animal models and clinical trials: (i) we predicted ab initio and in silico from first principles and validated a novel tumor suppressor microRNA (miR-204) that we have shown overtargeting oncogenes using sequence alignment and protein interaction network modeling, and (ii) we rescued a drug and repositioned another by computationally predicting ab initio mechanisms of head and neck cancers resistance to anti-EGFR therapy, validated biologically and evaluated a clinical trial the network-targeting combination therapy, (iv) we predicted and confirmed the biological underpinning of oligometastatic vs polymetastatic progression of human cancers, and developed a microRNA classifier predicting this condition that can be cured or controlled***, and (v) we have patented ex vivo blood assays for precision medicine such as single-patient sample interpretation of RNA-seq transcriptomes using mechanisms anchored in ontologies,, which predict future hospitalization of asthmatic patients (NIH-funded collaboration with Fernando Martinez) and may predict subjects at risk of disseminated valley fever (NIAID U01AI122275 MPI collaboration with John Galgiani, Steven Holland, and Jeffrey Frelinger), (vi) we submitted the 1st patent application to target drugs on intergenic risk factors of complex diseases , for which we are conducting additional validation before seeking venture capital funding (planner 2018), (vii) we expect to generate additional intellectual property in 2020 for for predicting risk factorrs of disseminated coccidiodomycosis.
 PLoS Comput Biol. 2010 Apr 1;6(4):e1000730
 Effect of the addition of temsirolimus to cetuximab in cetuximab-resistant head and neck cancers: Results of the randomized PII MAESTRO study; J Clin Oncol 2014 32:5s, #6089, grants 3UL1RR024999-03S3; NCI/CTEP
 PLoS ONE 6(12): e28650 ; ***PLoS ONE 7(12): e50141
 International Application PCT/US2014/058924, systems and methods for prediction personal therapeutic response
 J Am Med Inform Assoc 2014 21:1015-1025; best paper award at the Transl Bioinform Conf 2013
 Patent application 2016. Pharmacogenomics of Intergenic Single-Nucleotide Polymorphisms and in Silico Modeling for Precision Therapy.Arizona ref. no. UA16-224; L&G ref. no. 582806: 55-16P;
 NPJ Genom Med. 2016;1. pii: 16006. Epub 2016 Apr 27, highlight of the year award at the ISMB 2016 meeting of the International Society for Computational Biology.
- Post-Doctoral Fellowship, Canadian Research Council Fellow
- Columbia University, New York, US
- B. Engineering
- Université de Sherbrooke, Sherbrooke, CA
Licensure & Certification
- License of Medicine, Medical Council of Canada (1985)
- Family Medicine Board Certification, College of Family Physician of Canada (1991)
- Full Medical License, College of Physicians of Quebec (1991)
computational Precision medicine, Biomedical Ontologies, Clinical Information System, Knowledge Engineering and Decision Support Systems/Software/Methods, Translational Bioinformatics. Clinical Machine Leanring
Precision medicine, Translational Bioinformatics, Genomic Medicine, Clinical Case-Based Reasoning using machine learning
Introduction to ResearchMCB 795A (Spring 2017)
No activities entered.